Protein study aims to sharpen CLL diagnosis
NCT ID NCT07313982
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at a protein called LEF-1 in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers want to see if measuring LEF-1 can help make a more accurate diagnosis and find new clues about the disease. They will study tissue samples from 350 adults already diagnosed with CLL/SLL.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better diagnostic tools and new markers to guide treatment for CLL/SLL patients.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly change patient care or lead to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Irccs Azienda Ospedaliero-Universitaria Di Bologna
RECRUITINGBologna, BOLOGNA, 40138, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.